- •Adnexal neoplasia was found in ~5% of risk reduction surgeries for BRCA1 or BRCA2 mutations.
- •Recurrences developed from 9 to 17% over a median of 5 year follow-up.
- •There were no ovarian cancer-related deaths at 5 years.
This study computed the risk of clinically silent adnexal neoplasia in women with germ-line BRCA1 or BRCA2 mutations (BRCAm+) and determined recurrence risk.
We analyzed risk reduction salpingo-oophorectomies (RRSOs) from 349 BRCAm+ women processed by the SEE-FIM protocol and addressed recurrence rates for 29 neoplasms from three institutions.
Nineteen neoplasms (5.4%) were identified at one institution, 9.2% of BRCA1 and 3.4% of BRCA2 mutation-positive women. Fourteen had a high-grade tubal intraepithelial neoplasm (HGTIN, 74%). Mean age (54.4) was higher than the BRCAm+ cohort without neoplasia (47.8) and frequency increased with age (p < 0.001). Twenty-nine BRCAm+ patients with neoplasia from three institutions were followed for a median of 5 years (1–8 years.). One of 11 with HGTIN alone (9%) recurred at 4 years, in contrast to 3 of 18 with invasion or involvement of other sites (16.7%). All but two are currently alive. Among the 29 patients in the three institution cohort, mean ages for HGTIN and advanced disease were 49.2 and 57.7 (p = 0.027).
Adnexal neoplasia is present in 5–6% of RRSOs, is more common in women with BRCA1 mutations, and recurs in 9% of women with HGTIN alone. The lag in time from diagnosis of the HGTIN to pelvic recurrence (4 years) and differences in mean age between HGTIN and advanced disease (8.5 years) suggest an interval of several years from the onset of HGTIN until pelvic cancer develops. However, some neoplasms occur in the absence of HGTIN.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer facts and figures.American Cancer Society, Atlanta, Georgia, USA2013
- Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube.Diagn Histopathol. 2008; 14: 352-365
- Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship.Am J Surg Pathol. 2007; 31: 161-169
- Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.Gynecol Oncol. 2006; 100: 58-64
- The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.Am J Surg Pathol. 2006; 30: 230-236
- Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report.Gynecol Oncol. 2000; 77: 319-320
- Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.Gynecol Oncol. 2001; 80: 176-180
- Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.J Clin Oncol. 2005; 23: 127-132
- Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations.Hum Pathol. 2000; 31: 1420-1424
- Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.Int J Gynecol Pathol. 2004; 23: 29-34
- A candidate precursor to serous carcinoma that originates in the distal fallopian tube.J Pathol. 2007; 211: 26-35
- Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.J Clin Oncol. 2007; 25: 3985-3990
- Pathologic findings in prophylactic oophorectomy specimens in high-risk women.Gynecol Oncol. 2002; 87: 52-56
- Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.Gynecol Oncol. 2012; 127: 88-93
- Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.BJOG. 2011; 118: 814-824
- Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations.Am J Surg Pathol. 2004; 28: 1112-1114
- Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.Am J Surg Pathol. 2013; 37: 1123-1130
- Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).Int J Gynecol Cancer. 2013; 23: 1603-1611
- Support of the ‘fallopian tube hypothesis’ in a prospective series of risk-reducing salpingo-oophorectomy specimens.Eur J Cancer. 2013; 49: 132-141
- Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.Cancer Genet. 2012; 205: 34-41
- Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.Cancer. 2012; 118: 3703-3709
- Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.JAMA. 2006; 296: 185-192
- Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.Gynecol Oncol. 2013; 129: 364-371
- Through the glass darkly: intraepithelial neoplasia, top-down differentiation and the road to ovarian cancer.J Pathol. 2013; 231: 402-412
- Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.Fam Cancer. 2003; 2: 73-78
Published online: December 31, 2013
Accepted: December 5, 2013
Received: September 28, 2013
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.